Speaker information is updated as they are confirmed, please bookmark this site for later reference.
Robert C. Green, MD, MPH is a medical geneticist and physician-scientist who directs the Genomes2People Research Program in translational genomics and health outcomes at Brigham and Women’s Hospital, the Broad Institute and Harvard Medical School.
Dr. Green is accelerating the implementation of genomics into medicine by conducting rigorously designed research on medical, behavioral and economic outcomes of genomic testing. He leads the first randomized trials of clinical genome sequencing in adults (the MedSeq Project) and newborns (the BabySeq Project), and was recently awarded the first research project on clinical sequencing of personnel in the US Armed Forces.
He has been continuously funded by NIH for over 26 years and has published over 300 scientific papers. In 2014, he won the Coriell Prize for Scientific Achievement in Personalized Medicine. His work has been repeatedly highlighted on NBC Nightly News, the Today Show, CNBC, the New York Times, the Wall Street Journal, Time Magazine, New Scientist, FastCompany and Buzzfeed.
He has forged research collaborations with Genomics England, Illumina, 23andMe and Google; advises a number of biotechnology and genomics companies, and has co-founded an investor-backed telemedicine start-up company, Genome Medical, Inc. He has been invited to speak at the World Science Festival, Forbes Healthcare Summit, Exponential Medicine, JP Morgan Healthcare and South By Southwest.
Dr. Green graduated from Amherst College and the University of Virginia School of Medicine, and earned a Masters of Public Health in epidemiology from Emory University School of Public Health. He obtained specialty training at Harvard Medical School residencies and fellowships, and is board certified in both neurology and medical genetics.
Dr. William A. Gahl earned his BS degree in biology from the Massachusetts Institute of Technology in 1972 and his MD and PhD from the University of Wisconsin. He served as pediatric resident and chief resident at the University of Wisconsin hospitals from 1976-80. In 1984, he completed clinical genetics and clinical biochemical genetics fellowships at the NIH's Inter-Institute Medical Genetics Training Program, which he directed from 1989 to 1994. Dr. Gahl elucidated the basic defects in cystinosis and Salla disease and helped bring cysteamine to new drug approval by the Food and Drug Administration as the treatment for cystinosis. His group described the natural history of Lowe syndrome, alkaptonuria, autosomal recessive polycystic kidney disease, Chediak-Higashi disease, GNE myopathy, and Hermansky-Pudlak syndrome (HPS), and his lab discovered the genetic bases of gray platelet syndrome, Hartnup disease, arterial calcification due to deficiency of CD73, 3-methylglutaconic aciduria type III, 3 types of HPS, and neutropenia due to VPS45 deficiency.
Dr. Gahl has published more than 380 peer-reviewed papers, trained over 40 biochemical geneticists, and established American Board of Medical Specialties certification for medical biochemical genetics. He served on the board of directors of the American Board of Medical Genetics and American Society of Human Genetics, as President of the Society for Inherited Metabolic Disorders, and was elected to the American Society for Clinical Investigation and the Association of American Physicians. His accolades include the Dr. Nathan Davis Award for Outstanding Government Service from the American Medical Association, the Service to America Medal in Science and the Environment, the RareVoice Award for a Government Agency Leader, and numerous other awards.
Eric Dishman joined the National Institutes of Health in 2016 as the Director of the All of Us Research Program. In this role, he leads the agency’s efforts to build a national research cohort of one million or more U.S. participants to advance precision medicine.
Previously, Dishman was an Intel Fellow and Vice President of the Health and Life Sciences Group at Intel Corporation, where he was responsible for driving global strategy, research and development, product and platform development, and policy initiatives for health and life science solutions. His organization focused on growth opportunities for Intel in health IT, genomics and personalized medicine, consumer wellness, and care coordination technologies.
Trained as a social scientist, Dishman built all of his efforts at Intel upon a foundation of his and his team’s ethnographic fieldwork covering thousands of patient and provider experiences across more than 30 countries. He is known for pioneering innovation techniques that incorporate anthropology, ethnography, and other social science methods into the design and development of new technologies. He also brings his own experience as a cancer patient for 23 years—finally cured thanks to precision medicine—and his frequent patient advocacy to drive a person-centric view of health care transformation.
Dishman is widely recognized as a global leader in health care innovation with specific expertise in home and community-based technologies and services for chronic disease management and independent living. He and his team’s work have been featured in publications including The New York Times, The Washington Post, Business Week, and USA Today. The Wall Street Journal named him one of “12 People Who Are Changing Your Retirement.”
He also co-founded some of the world’s largest research and policy organizations devoted to advancing the cause of independent living, including the Technology Research for Independent Living Centre, the Center for Aging Services Technologies, the Everyday Technologies for Alzheimer’s Care program, and the Oregon Center for Aging and Technology. Dishman has received numerous awards for his work in helping to shape the future of health care.
Rob Knight, PhD, is the founding Director of the Center for Microbiome Innovation, an Agile Center in the Jacobs School of Engineering with the School of Medicine and the Division of Biological Sciences as founding partners, and is a Professor in UC San Diego’s Departments of Pediatrics and Computer Science & Engineering. Before that he was Professor of Chemistry & Biochemistry and Computer Science in the BioFrontiers Institute of the University of Colorado at Boulder, and an HHMI Early Career Scientist. Dr. Knight is a Fellow of the American Association for the Advancement of Science and of the American Academy of Microbiology. In 2015, he received the Vilceck Prize in Creative Promise for the Life Sciences. He is the author of “Follow Your Gut: The Enormous Impact of Tiny Microbes” (Simon & Schuster, 2015) and spoke at TED in 2014. His lab has produced many of the software tools and laboratory techniques that enabled high-throughput microbiome science, including the QIIME pipeline (cited over 5000 times as of this writing) and UniFrac (cited over 3000 times including its web interface). Dr. Knight is co-founder of the Earth Microbiome Project, the American Gut Project, and the company Biota, Inc., which uses DNA from microbes in the subsurface to guide oilfield decisions. His work has linked microbes to a range of health conditions including obesity and inflammatory bowel disease, has enhanced our understanding of microbes in environments ranging from the oceans to the tundra, and and made high-throughput sequencing techniques accessible to thousands of researchers around the world.
Joshua Coon, PhD is a professor of chemistry at the University of Wisconsin–Madison. He grew up in rural Michigan and during these formative years greatly enjoyed fly fishing and woodworking. Putting the latter interest to practical use, he constructed several riverboats (for fishing) while in high school and college. Chemistry interested him, especially Analytical Chemistry, as it offered an avenue to continue “building”. Not boats, but chemical instrumentation. To escape the cold he joined the Chemistry graduate program at the University of Florida and worked with Willard Harrison. Professor Harrison didn’t just guide his research, he taught him how to write, present, and think like a scientist. Upon graduation in 2002, Coon moved to Charlottesville, Virginia to join the laboratory of Professor Don Hunt. At Virginia he met John Syka. Don and John both shared a passion for science that was as infectious as it was inspiring. Together they worked to develop electron transfer dissociation (ETD). ETD worked just as we had hoped and the dissociation technique is now commonly used for proteomics and has been commercially introduced by no fewer than four major instrument vendors. In 2005 Coon moved to Wisconsin to start his own program. And though they have been productive and impactful with ~ 200 published manuscripts, he is most proud to have produced nearly 20 Ph.D. scientists, and their academic family continues to grow.
Muhammed Murtaza, MBBS, PhD is an Assistant Professor and Co-Director of the Center for Noninvasive Diagnostics at TGen, a non-profit research institute in Phoenix, AZ and jointly appointed at Mayo Clinic in Arizona. His group focuses on development of novel methods and applications for circulating tumor DNA analysis in cancer patients. Murtaza has published groundbreaking studies describing sequencing of circulating tumor DNA for tracking cancer burden and evolution. Prior to his current position, he received a PhD from the University of Cambridge and an MBBS (MD) from Aga Khan University in Pakistan.
Timothy B. Curry, MD, PhD, is the Director of the Education Program of the Mayo Clinic Center for Individualized Medicine. A clinical anesthesiologist, he and his team are helping provide the education to support the translation of individualized medicine and develop the next generation of researchers and clinicians in personalized medicine.
Steven C Greenway, MSc, MD, FRCPC is a pediatric cardiologist and Clinician-Investigator in the Section of Cardiology at the Alberta Children's Hospital and an assistant professor in the Departments of Paediatrics, Cardiac Sciences and Biochemistry & Molecular Biology at the University of Calgary in Calgary, Alberta, Canada. He is a member of the Alberta Children's Hospital Research Institute and the Libin Cardiovascular Institute of Alberta. After completing an MSc degree in the laboratory of Dr Kenneth Storey at Carleton University he completed medical school at the University of Manitoba. Residency in Paediatrics and fellowships in Pediatric Cardiology and Heart Function and Transplantation were completed at The Hospital for Sick Children in Toronto. Clinical training was interrupted by a postdoctoral fellowship supported by the Pediatric Scientist Development Program in the Seidman laboratory at Harvard Medical School. Dr Greenway has been in Calgary since 2012 with research interests in translational genomics.
Erik Ingelsson, MD, PhD is Professor of Medicine at Stanford University. His main area of interest is the link between metabolic disturbances, such as obesity and insulin resistance, and the development of subclinical and clinical cardiovascular disease. His research is translational and interdisciplinary, combining methods from the molecular epidemiology field (genomic, metabolomic, transcriptomic, epigenomic and proteomic profiling in large population-based studies) with in-vivo and in- vitro work. This allows new insights into the pathophysiology of cardiovascular disease and related conditions, identification of new biomarkers for improved risk prediction, and discovery of novel targets for drug development.
Dr. Inglesson has had a leading role in many of the large efforts identifying new loci associated with cardiovascular and metabolic traits. He also has extensive experience from research on biomarkers and -omics methods, including development and use of prediction metrics and Mendelian randomization. He has served as PI of numerous –omics efforts in several Swedish cohort studies, including ULSAM, PIVUS, TwinGene and EpiHealth. Since 2014 and on, he has also built a team working with characterization of loci established in GWAS using different functional model systems. He has published over 240 peer-reviewed publications, of which >50 in journals with impact factor over 30. Before relocating to the U.S, he was Professor of Cardiovascular Epidemiology at Karolinska Institutet, Stockholm, Sweden (2010-2013) and Professor of Molecular Epidemiology at Uppsala University (2013-2016). He has been very successful in obtaining extramural funding, and has won many prestigious awards and grants, such as the AHA Trudy Bush Fellowship for Cardiovascular Research in Women’s Health, ERC starting grant, Wallenberg Academy Fellow and the Göran Gustafsson Prize in Medicine in 2015 (to the most successful medical researcher in Sweden under age 45).
Kisiel, MD of Mayo Clinic in Rochester, Minnesota, is Assistant Professor of Medicine and a Consultant in the Division of Gastroenterology and Hepatology. After receiving his M.D. from the University of Illinois, he went on to the Mayo School of Graduate Medical Education (MSGME). At MSGME, he completed his internal medicine & chief medicine residencies, GI neoplasia & gastroenterology fellowships, as well as a master's degree in Clinical & Translational Research.
As a researcher in the GI Cancer Molecular Diagnostics laboratory, his work is focused on the discovery and clinical development of non-invasive biomarkers for the detection of colorectal, hepatobiliary and pancreatic cancers. He is a member of the Mayo Clinic Center for Individualized Medicine Epigenomic Scientific Committee and Epigenomic Advisory Group and has an active clinical practice in inflammatory bowel disease and gastrointestinal endoscopy.
W. David Mauck, MD is a graduate from the University of Missouri-Columbia where he received his MD degree. He then served four years in the United States Air Force as a Flight Surgeon. Following this commitment, he returned to training and completed his Anesthesiology residency in 2002 at the Mayo Clinic in Rochester Minnesota. In 2002 he was awarded the Mayo Foundation Scholar and completed a Pain Medicine Fellowship at the Mayo Clinic in Rochester. Following the fellowship, he was hired at Mayo Clinic in Rochester as an Anesthesiology and Pain Medicine consultant. In 2007 he left the practice of anesthesiology and focuses his full attention on the practice Pain Medicine. He holds the position of Assistant Professor of Anesthesiology and Pain Medicine at the Mayo Clinic College of Medicine and is the Chairman of the Pain Medicine Division. He staffs both the Spine Center and Pain Medicine Clinic where he collaborates with PMR, Oncology, Palliative Medicine, Neurology and surgical colleagues. Dr. Mauck has an interest in expanding the role and therapies offered by Pain Medicine, particularly those involving neuromodulation. He continues to actively lecture and publish on Pain Medicine treatment and therapies.
Paldeep Atwal, MB, ChB is a clinical and medical biochemical geneticist at Mayo Clinic FL and serves as Medical Director for the Center for Individualized Medicine on the Jacksonville campus, having joined the Mayo Clinic in 2015. He received his medical degree from the University of Glasgow, and initially trained in hospital internal medicine with The Royal College of Physicians at Glasgow Royal Infirmary in Scotland. He did his genetics fellowship at Stanford University and subspecialty biochemical genetics fellowship at Baylor College of Medicine where he was involved in developing a clinical metabolomic profiling test. In addition he holds diplomas in structural molecular biology and forensic medical science.
He has a long standing interest in rare and undiagnosed disease including the use of multiple concurrent –omics platforms to provide a diagnosis to patients.
Dr. Atwal’s clinical interests include clinical genomics, undiagnosed disease following lengthy diagnostic odysseys and inborn errors of metabolism including mitochondrial diseases.
Dr. Atwal’s awards include the 2014-2015 ACMG Foundation/Genzyme Fellowship in Biochemical Genetics Award and The Neurobiology of Disease in Children Young Investigator Award.